TCTR20220331004尚未招募1 期
An Open Label, Crossover Bioequivalence Study of DALAVIR Tablets of the Government Pharmaceutical Organization, Thailand with TIVICAY (Dolutegravir 50 mg tablets) +EPIVIR (Lamivudine 300 mg tablets) VIREAD (Tenofovir disoproxil fumarate 300 mg tablets) in Healthy Subjects under Fasting Conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •a) Non-smokers, normal, healthy, adult, both males and females subjects between 18 and 55 years of age (both inclusive).
- •b) Having a Body Mass Index (BMI) between 18.0 and 30.0 (both inclusive), calculated as weight in kg/height in m2.
- •c) Not having significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12 lead ECG, and chest X-ray recordings (postero-anterior view).
- •d) Able to understand and comply with the study procedures, in the opinion of the investigator.
- •e) Able to give voluntary written informed consent for participation in the trial.
- •f) In case of female subjects:
- •- Surgically sterilized at least 06 months prior to study participation; Or
- •- If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study. And
- •- Urine pregnancy test must be negative.
排除标准
- •a) Known hypersensitivity to dolutegravir, lamivudine or tenofovir disoproxil fumarate or any excipients or any related drug or any substance.
- •b) History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •c) Subjects who are being or have previously been treated for any GI problems or convulsive, depressive or hepatic disorders, and in whom there is a risk of a recurrence during the study period.
- •d) Ingestion or use of any medication (prescribed medication & over the counter (OTC) medication including herbal remedies and St. John Wort is at any time in 14 days prior to dosing of period-I. In any such case subject selection will be at the discretion of the Principal Investigator.
- •e) Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
- •f) Consumption of grapefruits and grapefruit products within a period of 72 hours prior to dosing in Period-I.
- •g) Consumption of xanthine containing food or beverages (tea, coffee, chocolates or cola drinks), tobacco, tobacco containing products 24 hours prior to IMP administration of period-I.
- •h) Smokers or who have smoked within last 06 months prior to start of the study.
- •i) A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40 persent distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period-I.
- •j) The presence of clinically significant abnormal laboratory values during screening.
- •k) Use of any recreational drugs or history of drug addiction or testing positive in pre study drug scans.
- •l) History or presence of seizure or psychiatric disorder. m) A history of difficulty with donating blood.
- •n) Difficulty in swallowing solids dosage forms like tablets or capsules.
- •o) Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
- •p) Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.
- •q) A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.
- •r) A positive test result for HIV antibody.
- •s) A positive test result for COVID-19 RT-PCR test through the nasopharyngeal swab.
- •t) An unusual diet, for whatever reason (for example, fasting, high potassium or low-sodium), for four weeks prior to receiving the study drug in period I. In any such case subject selection will be at the discretion of the Principal Investigator.
- •u) Nursing mothers (for female subjects).
研究者
相似试验
尚未招募
1 期
An Open Label, Crossover Bioequivalence Study of DALAVIR Tablets of the Government Pharmaceutical Organization, Thailand with TIVICAY (Dolutegravir 50 mg tablets) +EPIVIR (Lamivudine 300 mg tablets) VIREAD (Tenofovir disoproxil fumarate 300 mg tablets) in Healthy Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20210913002The Government Pharmaceutical Organization52
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Empagliflozin 25 mg tablets relative to Jardiance 25 mg, in healthy Thai volunteers under fasting conditioHealthy subjectsBioequivalence Empagliflozin 25 mg tabletsTCTR20240319011Bio-innova Co., Ltd.32
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, full replicate crossover design with four-period, two-treatment, and two-sequence of Fexofenadine 180 mg tablets relative to Telfast 180 mg tablets in healthy Thai volunteers under fasting condition.Healthy subjectsBioequivalence Fexofenadine 180 mg tabletsTCTR20230915004Bio-innova Co., Ltd.30
尚未招募
1 期
A Bioequivalence study of a randomized,open-label,single dose,two-way crossover with two-period, two-treatment and two-sequence of Erythropoietin-SBS 4000 IU, 0.4 ml in syringe subcutaneous injection relative to Hema-Plus 4000 prefilled syringes in healthy Thai volunteers under fasting conditioHealthy subjectsErythropoietin bioequivalenceTCTR20210519004Bio-innova and Synchron.Co.,Ltd24
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Apixaban 5 mg tablets, relative to ELIQUIS 5 mg tablets in healthy Thai volunteers under fasting conditioHealthy subjectsBioequivalence Apixaban 5 mg tabletsTCTR20230714002Bio-innova Co., Ltd.26